Debiopharm Group: Debiopharm Group™ (Debiopharm) is a privately held bio-pharmaceutical company based in Lausanne, Switzerland. Debiopharm focuses on the development of innovative prescription drugs targeting unmet medical needs. Its lead candidate, Debio 025 (alisporivir) is a first-in-class cyclophilin inhibitor, which could become part of the future standard of care for hepatitis C. Debiopharm entirely funds all its development activities.
NB Health Laboratory Co., Ltd.: NB Health Laboratory Co., Ltd. is a privately held biotechnology company based in Kawaguchi, Japan. NB Health is focused on conducting unique drug discovery programs for sleeping disorder with dementia, autoimmune diseases and respiratory diseases such as lung inflammation, COPD and cancer since 2007. Their lead candidates include, #P001, in its Preclinical Phase for Autoimmune diseases and COPD, #P007, in its Preclinical Phase for Fibrosis, #P005, also in its Preclinical Phase for Sleeping disorder and Alzhemimer's, and #P003, in its Diagnostics Phase for COPD.
Neovacs SA: Neovacs is a biotechnology company built on a next generation active immunotherapy technology platform, focused on the treatment of severe, chronic autoimmune diseases. The Company has a leadership position in active immunotherapy directed at cytokine targets, with two candidates in clinical testing in three indications: rheumatoid arthritis, Crohn's Disease and lupus.
Addex Pharmaceuticals: Addex Pharmaceuticals discovers and develops an emerging class of small molecule drugs, called allosteric modulators, which have the potential to be more specific and confer significant therapeutic advantages over conventional “orthosteric” small molecule or biological drugs.
Intellect Neurosciences, Inc.: Intellect Neurosciences, Inc. develops innovative approaches aimed at arresting or preventing Alzheimer’s disease, and other neurodegenerative diseases, especially focused on proteinopathies. Intellect’s pipeline includes therapeutic vaccines, antibodies and neuroprotective antibody drug conjugates.
Intra-Cellular Therapies: Intra-Cellular Therapies, Inc., (ITI) based in New York, New York, is a privately held biopharmaceutical company that develops novel drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the Central Nervous System (CNS). The company's lead product, ITI-007 is a novel first-in-class 5-HT2A antagonist, Dopamine receptor phosphoprotein modulator (DPPM), glutamatergic phosphoprotein modulator and SERT inhibitor designed to treat multiple deficits in patients with schizophrenia while lacking the side-effects of existing antipsychotic drugs. ITI has also developed a state of the art technology platform, called CNSProfile™ that is capable of generating a unique molecular signature for drug compounds.
Kareus Therapeutics: Kareus Therapeutics is from La Chaux-de-Fonds, Switzerland and is a privately held biotechnology company focused on discovery and development of novel small molecule drugs based upon its proprietary KARLECT chemistry platform. Kareus has small molecule drug discovery in Diabetes, Inflammation and Alzheimer's Disease and their technology allows novel combinations of drugs to be created with improved therapeutic and safety profiles using a new approach.
Chiome Biosciences Inc.: Chiome Bioscience Inc. was established in 2005 after receiving official authorization as a RIKEN Venture Enterprise. Chiome has a very unique platform technology named the “ADLib System” by accelerating gene conversion in Immuno Globulin loci. The “ADLib System” can provide unparalleled speed for novel antibody generation and adaptability to diverse antigens. Chiome successfully developed the cell-cell interaction method named the “ADLib axCELL” to overcome cell surfaced antigens including GPCRs. Chiome also launched the Chimera Mouse IgG ADLib System in 2011. Chiome has partnership with Chugai Pharmaceutical Co. Ltd., Fiveprime Therapeutics Inc. and OncoMed Inc. Chiome is seeking alliance partners all over the world.
Interprotein: Interprotein is focusing on two program, the discovery research and development of synthetic small molecule protein-protein interaction inhibitors by novel drug design method (INTENDD) and improvement biologics production yield by enhancer gene, CIRP technology.
Connexios Life Sciences Pvt Ltd: Connexios is a venture-backed company established in 2003. We are building a broad innovative clinical pipeline that aims to address the critical clinical gaps in Type 2 Diabetes
Apricus Biosciences: Apricus Bio is a San Diego-based, revenue-generating, specialty pharmaceutical company, with commercial products and a broad pipeline across numerous therapeutic classes.Revenues and growth are driven from the sales of the Company's commercial products through its Apricus Pharmaceuticals USA, Inc. and NexMed (USA), Inc. subsidiaries and through out-licensing in certain territories of its product pipeline and NexACT® technology. Apricus Bio's current pipeline includes Vitaros®, approved in Canada for the treatment of erectile dysfunction, Totect® the only drug approved in the US for the treatment of anthracycline extravasation, as well as compounds in development from pre-clinical through pre-registration currently focused on Sexual Dysfunction, Oncology, Dermatology, Autoimmune, Pain, Anti-Infectives, Diabetes and Consumer Healthcare.
Dicerna Pharmaceuticals: Dicerna Pharmaceuticals is developing next generation RNA interference (RNAi) therapeutics in oncology and other disease areas, based on its proprietary Dicer Substrate siRNA (DsiRNA) Technology™ platform and proprietary DsiRNA drug delivery technologies. Dicerna’s internal programs are focused on high value, otherwise undruggable oncology targets, creating first-in-class programs with robust efficacy in indications such as hepatocellular carcinoma.
Immune Targeting Systems Ltd: Immune Targeting Systems (ITS) is a London based Biotech Company developing vaccines for mutating viruses and cancer underpinned by its DepoVaccine™ & Densigen™ technology platforms. ITS’ lead program, a synthetic universal influenza vaccine (Flunisyn™) targeting all potential seasonal and pandemic flu strains, has completed phase-I clinical testing. Phase-1b / 2a clinical studies will initiate in 2012.
Korea Research Institute of Chemical Technology: KRICT is the only government-supported research institution in chemical technology of Korea.Since the establishment in 1976, KRICT has contributed to the growth of the domestic chemical industry and is now endeavoring to develop key chemical technologies to secure a sustainable future for the planet and its people.
Affimed AG: Affimed Therapeutics AG is a clinical stage company developing bispecific RECRUIT-TandAb antibodies in oncology and has two products in development in lymphoma indications. TandAbs possess increased therapeutic potential compared to monoclonal antibodies. They are well expressed, possess drug-like properties and show excellent product stability.
CytomX Therapeutics, Inc.: CytomX Therapeutics, Inc is a venture backed biotechnology company developing Probodies™, proteolytically-activated antibodies. Probodies, by the ability to site-direct the activity of antibodies, will result in an improved therapeutic index for validated targets, as well as enable the drugging of targets with broad tissue expression. CytomX has demonstrated in-vivo that Probodies are inert in circulation and healthy tissue but active in diseased tissue.
Ezose Sciences: Ezose Sciences is a leading Glycomics R&D company that provides state-of-the-art solutions for glycan analysis. Ezose Sciences' technology, the GlycanMAP platform offers a new high throughput solutions and can deliver both qualitative and quantitative data on glycans of biological and clinical interest across a range of biological sample types, using a fully automated robotic platform. Ezose partners with pharmaceutical and biotech companies are to apply our novel technology to the discovery and application of new biomarkers for the treatment and diagnosis of disease. We also apply our technology to Biologics drug manufacturing/development as an analytical tool. Ezose was founded in 2009 to commercialize the technology.
Marshall Edwards Inc.: Marshall Edwards, Inc. (Nasdaq: MSHL) is a San Diego-based oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism. Its two lead compounds, ME-143 and ME-344, show robust activity against a broad range of tumor cell lines of diverse tissue origin. The Company expects final data from its Phase I clinical trial of ME-143 in patients with solid refractory tumors in the second quarter of 2012.
SFJ Pharmaceuticals: SFJ Pharma Group provides large Pharma incremental budget, 100% at risk, & resourcing for their most promising drugs in late-stage clinical development. In the last 6 months SFJ has agreed to fund a large pan-Asian Phase III oncology study on behalf of Pfizer and a global Phase III oncology study on behalf of Eisai.
Spectrum Pharmaceuticals: Spectrum Pharmaceuticals, a biotechnology company with a primary focus in oncology and hematology, currently markets two oncology drugs, FUSILEV® and ZEVALIN®, followed by two drugs, apaziquone and belinostat, in late stage development with a goal of filing New Drug Applications (NDAs) with the U.S. Food & Drug Administration in 2012. The Company also has a diversified pipeline of novel drug candidates. The Company's strategy is comprised of acquiring, developing and commercializing a broad and diverse pipeline of late-stage clinical and commercial drug products.
ABSize Inc. : ABsize is a privately-held nanotechnology / nano-medicine company. Backed by Japanese VCs, ABsize is a spin-off from Osaka University in 2007 based on its proprietary technology platform, Laser-induced Nanolization Technology (LiNTEC). ABsize is developing a proprietary best-in-class product pipeline and partnering with pharma / biotech companies to help develop their new products.
MEDIPOST Co., Ltd.: MEDIPOST is a leading stem cell biotechnology company based in Seoul, Korea. MEDIPOST is developing adult stem cell drug products to meet unmet medical needs such as regeneration and functional recovery of knee articular cartilage, the central nervous system, the pulmonary system and hematopoietic transplantation engraftment areas.
Vivus, Inc.: VIVUS is a US-based biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes, obstructive sleep apnea and sexual health. Qnexa® (low-dose phentermine/topiramate), the company’s lead product in clinical development, has completed Phase 3 clinical trials and is under Regulatory review in the U.S. and EU for the treatment of obesity. Avanafil, the company's highly selective oral phosphodiesterase type 5 (PDE5) inhibitor, is under Regulatory review for the treatment of erectile dysfunction.
Protein Sciences Corporation: Protein Sceinces utilizes their proprietary baculovirus expression vector technology, including the patented expresSF+® (SF+) insect cell line, to produce novel prophylactic and therapeutic vaccines, monoclonal antibodies and vectors for gene therapy such as rAAV for customers worldwide, including many in Japan. Protein Sciences produces all products in the SF+ cell line, which eliminates the need to create a new cell line for each product and allows their customers to take advantage of the extensive regulatory pathway that has been established in the U.S., Japan, E.U. and other countries.
For presenting company websites and stock information please see our 2012 Presenting Companies page.
See here for company description disclaimer.